Nathanael Gray, PhD

Nancy Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology in the Field of Medical Oncology, Dana-Farber Cancer Institute
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.
Authors: Authors: Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA.
Nat Commun
View full abstract on Pubmed
Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5.
Authors: Authors: Gilbert AS, Seoane PI, Sephton-Clark P, Bojarczuk A, Hotham R, Giurisato E, Sarhan AR, Hillen A, Velde GV, Gray NS, Alessi DR, Cunningham DL, Tournier C, Johnston SA, May RC.
Sci Adv
View full abstract on Pubmed
Discovery of a potent dual ALK and EGFR T790M inhibitor.
Authors: Authors: Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.
Eur J Med Chem
View full abstract on Pubmed
A benzo[b]thiophene-based selective type 4 S1P receptor agonist.
Authors: Authors: Hur W, Rosen H, Gray NS.
Bioorg Med Chem Lett
View full abstract on Pubmed
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Authors: Authors: Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP.
Blood
View full abstract on Pubmed
The ins and outs of selective kinase inhibitor development.
Authors: Authors: Müller S, Chaikuad A, Gray NS, Knapp S.
Nat Chem Biol
View full abstract on Pubmed
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Authors: Authors: Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA.
Clin Cancer Res
View full abstract on Pubmed
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Authors: Authors: Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.
Oncotarget
View full abstract on Pubmed
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.
Authors: Authors: Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, Gray NS, Mitchison TJ, Zhao JJ.
Elife
View full abstract on Pubmed
Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.
Authors: Authors: Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny GD, Galinsky I, Stone RM, Gray NS, D'Andrea AD, Parmar K.
Mol Cancer Ther
View full abstract on Pubmed